Navigation Links
Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
Date:2/20/2013

tect molecular signs of tumor response to therapy after only 2 days. A change in blood flow in the tumor was observed to detect response after day 14 using DCE-PI. Over the same period, standard volume measurements were not able to detect therapeutic response, and prior studies suggested that volume measurements do not become indicative of response until approximately 28 days. Thus, these methods showed a notable improvement in the early identification of tumor response to therapy, using contrast enhanced ultrasound imaging.

Although the contrast agents for USMI are not yet available in the United States, they are currently in clinical trials in Europe for cancer imaging.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina Health Care
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Preclinical studies use specialized ultrasound to detect presence of cancer
2. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
3. Virology researcher awarded nearly $2 million to study chronic hepatitis E
4. New study shows how seals sleep with only half their brain at a time
5. Study shows that diet of resistant starch helps the body resist colorectal cancer
6. Breakthrough study opens door to broader biomedical applications for Raman spectroscopy
7. Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study
8. Yale Study links common chemicals to osteoarthritis
9. CU-Boulder amphibian study shows how biodiversity can protect against disease
10. Busy beavers give Canada geese a lift, study shows
11. Video study shows which fish clean up coral reefs, showing importance of biodiversity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2
... A new assessment of the Arctic,s biodiversity reports a 26 ... Populations of lemmings, caribou and red knot are some ... 34 years, according to the first report from The Arctic ... the Arctic,s ecosystems and wildlife are responding to environmental change. ...
... by Wayne L. Backes, PhD, Professor of Pharmacology and Associate ... School of Medicine, has found that drug metabolism depends not ... also how they interact, and that can be the difference ... or is converted into a toxic or carcinogenic byproduct. The ...
... Angeles, Calif., March 16, 2010Researchers at the Keck School ... have identified a key cellular mechanism that guides embryonic ... to a number of common congenital heart defects. ... the First Heart Field, which includes the left ventricle ...
Cached Biology News:High Arctic species on thin ice 2LSUHSC research increases understanding of drug metabolism 2USC researchers identify key mechanism that guides cells to form heart tissue 2
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be ... cell credentialing course to local area veterinarians. , The tour and course will be ... at no charge) at VetStem’s Poway facility. Staff members are welcome to attend with ...
(Date:7/28/2015)... , July 28, 2015  Kerastem Technologies announce ... from the U.S. FDA Center For Biologics Evaluation and ... to conduct a clinical trial investigating the safety and ... female and early male pattern baldness (androgenic alopecia). ... trial, follows initial clinical work in Europe ...
(Date:7/28/2015)... OF PRUSSIA, Pa. , July 28, 2015 /PRNewswire/ ... U.S. Food and Drug Administration has accepted for review ... investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment ... met all primary endpoints. Hemophilia ... deficient or defective factor VIII; nearly all affected patients ...
(Date:7/28/2015)... , July 28, 2015 ... company utilizing its proprietary plant-based rhCollagen technology for ... has been appointed Senior Director of Business Development, ... http://photos.prnewswire.com/prnh/20150728/246955 ) , Ms. ... marketing, regulatory and business strategy. Prior to joining ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
... Safety Nets to Prevent Serious Health Hazards ... Associated with ... U.S. Pharmacopeial (USP),Convention today announced a revised Glycerin monograph ... the United States. The,revision strengthens safety nets to prevent ...
... March 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ... Dr. Kevin,Harrington and his research group at ... the results of their work characterizing immune,system ... a Phase I,clinical trial. The paper, entitled ...
... by the Greater Baltimore Committee:, WHO:, Donald ... 140 company owners, executives and researchers from the Baltimore-area,bioscience ... Region Bioscience Awards, WHEN:, Tuesday, March 18, ... 8:45 - 9:30 a.m. / Awards Program, WHERE:, ...
Cached Biology Technology:USP Announces Revised Glycerin Monograph 2USP Announces Revised Glycerin Monograph 3Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial 2Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Phospho-FAK (Tyr576/577) Antibody...
Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Biology Products: